Assenagon Asset Management S.A. Bellus Health Inc. Transaction History

Assenagon Asset Management S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 18, 2023	BUY	$7.14 - $8.53 $1.65 Million - $1.97 Million	230,956 Added 50.61%	687,277 $4.95 Million
Q4 2022 Jan 12, 2023	SELL	$8.22 - $10.76 $2.89 Million - $3.78 Million	-351,676 Reduced 43.52%	456,321 $3.75 Million
Q3 2022 Oct 27, 2022	SELL	$8.95 - $12.0 $474,663 - $636,420	-53,035 Reduced 6.16%	807,997 $8.53 Million
Q2 2022 Jul 27, 2022	BUY	$6.46 - $10.02 $3.32 Million - $5.15 Million	513,785 Added 147.96%	861,032 $7.96 Million
Q1 2022 Apr 25, 2022	BUY	$5.56 - $7.99 $1.93 Million - $2.77 Million	347,247 New	347,247 $2.39 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.